The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Comparing the outcomes of patients with LBCL receiving alloSCT versus anti-CD19 CAR-T therapy
Alberto Mussetti, MD, Catalan Institute of Oncology, Barcelona, Spain, discusses the results of a study which compared the use of anti-CD19 CAR-T cells versus allogeneic stem cell transplantation (alloSCT) to treat patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Results demonstrated that overall survival (OS) outcomes in both groups were similar, however, there was a higher rate of non-relapse mortality in the alloSCT group. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Consultancy; Takeda: Honoraria; Gilead: Research Funding; Jazz Pharmaceuticals: Consultancy.
